SIRT1 is an actionable target to restore p53 function in HPV-associated cancer therapy.

Background: Our aim was to evaluate the efficacy and anti-cancer action of a precision medicine approach involving a novel SIRT1-dependent pathway that, when disrupted, leads to the restoration of a functional p53 in human papillomavirus (HPV)-transformed cells.
Methods: The anticancer potential of inhibiting SIRT1 was evaluated by examining the effects of the specific SIRT1 inhibitor EX527 (also known as Selisistat) or genetic silencing, either individually or in conjunction with standard chemotherapeutic agents, on a range of HPV ⁺ cancer cells and a preclinical mouse model of HPV16-induced cancer.
Results: We show that SIRT1 inhibition restores a transcriptionally active K382-acetylated p53 in HPV ⁺ but not HPV ^- cell lines, which in turn promotes G ₀ /G ₁ cell cycle arrest and inhibits clonogenicity specifically in HPV ⁺ cells. Additionally, EX527 treatment increases the sensitivity of HPV ⁺ cells to sublethal doses of standard genotoxic agents. The enhanced sensitivity to cisplatin as well as p53 restoration were also observed in an in vivo tumorigenicity assay using syngeneic C3.43 cells harbouring an integrated HPV16 genome, injected subcutaneously into C57BL/6J mice.
Conclusions: Our findings uncover an essential role of SIRT1 in HPV-driven oncogenesis, which may have direct translational implications for the treatment of this type of cancer.
(© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)